Kevin Anderson, MD
Family Medicine · Cadillac, MINPI 1942202916
Payments from drug & device makers
Across 327 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Shionogi Inc$975
- Novo Nordisk$571
- Pfizer$517
- Boehringer Ingelheim$464
- Pinnacle, Inc$410
- plus $2K from 32 others
What the payments were for
- Consulting fees$97515%
- Travel & lodging$2985%
- Food & beverage$4,96878%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,015 |
| Shionogi Inc | 1 | $975 |
| Novo Nordisk | 31 | $571 |
| Pfizer | 39 | $517 |
| Boehringer Ingelheim | 22 | $464 |
| Pinnacle, Inc | 2 | $410 |
| Astellas Pharma US Inc | 16 | $310 |
| Lilly USA, LLC | 21 | $289 |
| GSK | 40 | $284 |
| Amgen | 15 | $238 |
| AstraZeneca | 10 | $215 |
| Exact Sciences | 7 | $126 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Merck | 3 | $61 |
| Radius Health, Inc. | 3 | $51 |
| Dexcom, Inc. | 2 | $49 |
| Johnson & Johnson | 4 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Supernus Pharmaceuticals, Inc. | 3 | $41 |
| Medtronic | 1 | $38 |
| Antares Pharma, Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Indivior Inc. | 1 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $26 |
| Corium, LLC | 1 | $25 |
| Lundbeck LLC | 1 | $25 |
| Verona Pharma, Inc. | 1 | $24 |
| Neurelis, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Abbott | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,352 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 164 | $221,083 |
| EliquisApixaban | 158 | $154,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $143,388 |
| JardianceEmpagliflozin | 152 | $141,883 |
| FarxigaDapagliflozin Propanediol | 68 | $64,071 |
| TrulicityDulaglutide | 54 | $61,843 |
| OzempicSemaglutide | 39 | $54,980 |
| JanuviaSitagliptin Phosphate | 55 | $43,724 |
| MyrbetriqMirabegron | 36 | $26,017 |
| XareltoRivaroxaban | 30 | $24,182 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $21,283 |
| GlyxambiEmpagliflozin/Linagliptin | 16 | $20,732 |
| OxycontinOxycodone Hcl | 25 | $20,500 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $19,390 |
| Xtampza ErOxycodone Myristate | 11 | $12,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $289 | $282,926218 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $284 | $172,564196 claims |
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat | $464 | $168,631179 claims |
| PfizerEliquis | $517 | $154,439158 claims |
| AstraZenecaFarxiga, Symbicort | $215 | $71,21385 claims |
| Novo NordiskOzempic | $571 | $54,98039 claims |
| MerckJanuvia | $61 | $43,72455 claims |
| Astellas Pharma US IncMyrbetriq | $310 | $26,01736 claims |
| Johnson & JohnsonXarelto | $48 | $24,18230 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Motegrity | $63 | $14,28328 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $26 | $12,64011 claims |
| AbbVieLinzess | $1,015 | $10,28820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Cadillac
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.